以全标本组织病理学为参考头对头比较18F-PSMA-1007正电子发射断层扫描/计算机断层扫描与多参数磁共振成像在前列腺癌原发灶定位与分期中的价值
前瞻性纳入105例活检证实为中危或高危、接受机器人辅助根治性前列腺切除术的原发性前列腺癌患者,以全标本组织病理学为参考,比较18F-PSMA-1007 PET/CT与mpMRI对前列腺内肿瘤定位及前列腺外侵犯和精囊侵犯的诊断效能。结果显示PSMA PET/CT对临床显著前列腺癌的病灶灵敏度高于mpMRI,但在检测前列腺外侵犯和精囊侵犯方面未见额外价值。
要点
- PSMA PET/CT对临床显著前列腺癌的病灶灵敏度为95%,高于mpMRI的73%(p < 0.001)。
- PSMA PET/CT与mpMRI检测前列腺外侵犯的灵敏度与特异度均无显著差异。
- PSMA PET/CT与mpMRI检测精囊侵犯的灵敏度与特异度均无显著差异。
核心结论
- 18F-PSMA-1007是定位前列腺内临床显著前列腺癌的有前景的影像方法,但与mpMRI相比在评估前列腺外侵犯和精囊侵犯方面未显示额外价值。
研究设计与样本
- 前瞻性纳入2019年2月至2020年10月间105例活检证实为中危或高危、未接受治疗的原发性前列腺癌患者,均在机器人辅助根治性前列腺切除术前行mpMRI和18F-PSMA-1007 PET/CT。
- 以根治性前列腺切除全标本组织病理学检查为参考,计算灵敏度、特异度、阴性预测值、阳性预测值和准确率,采用McNemar检验比较两种影像方法。
主要发现
- 在80例根治性前列腺切除标本中发现129个前列腺癌病灶,其中96个为临床显著前列腺癌。
- 总体前列腺癌定位的病灶灵敏度:PSMA PET/CT为85%(95%CI 77-90%),mpMRI为62%(95%CI 53-70%)(p < 0.001)。
- 临床显著前列腺癌的病灶灵敏度:PSMA PET/CT为95%(95%CI 88-98%),mpMRI为73%(95%CI 63-81%)(p < 0.001)。
- 检测前列腺外侵犯的灵敏度:PSMA PET/CT为45%(95%CI 31-60%),mpMRI为55%(95%CI 40-69%)(p = 0.3);特异度:PSMA PET/CT为85%(95%CI 75-92%),mpMRI为90%(95%CI 81-86%)(p = 0.5)。
- 检测精囊侵犯的灵敏度:PSMA PET/CT为47%(95%CI 21-73%),mpMRI为33%(95%CI 12-62)(p = 0.6);特异度:PSMA PET/CT为94%(95%CI 88-98%),mpMRI为96%(95%CI 90-99%)(p = 0.8)。
临床怎么用
- 原文结论指出18F-PSMA-1007是定位前列腺内临床显著前列腺癌的有前景的影像方法,但与mpMRI相比在评估前列腺外侵犯和精囊侵犯方面未显示额外价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate local staging is critical for treatment planning and prognosis in prostate cancer (PCa). Although multiparametric magnetic resonance imaging (mpMRI) has high specificity for detection of extraprostatic extension (EPE) and seminal vesicle invasion (SVI), its sensitivity remains limited. 18F-PSMA-1007 positron emission tomography/computed tomography (PET/CT) may be more accurate in determining T stage. OBJECTIVE: To assess the diagnostic performance of 18F-PSMA-1007 PET/CT in comparison to mpMRI for intraprostatic tumour localisation and detection of EPE and SVI in men with primary PCa undergoing robot-assisted radical prostatectomy (RARP). DESIGN, SETTING, AND PARTICIPANTS: Between February 2019 and October 2020, 105 treatment-naïve patients with biopsy-proven intermediate- or high-risk PCa undergoing mpMRI and 18F-PSMA-1007 PET/CT before RARP were prospectively enrolled. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The diagnostic accuracy of 18F-PSMA-1007 PET/CT and mpMRI for intraprostatic tumour localisation and detection of EPE and SVI was assessed via histopathological examination of whole-mount RP specimens. The sensitivity, specificity, negative predictive value, positive predictive value, and accuracy were calculated. The McNemar test was used to compare outcomes between imaging modalities. RESULTS AND LIMITATIONS: In 80 RP specimens, 129 PCa lesions were found, of which 96 were clinically significant PCa (csPCa). Per-lesion sensitivity for localisation of overall PCa was 85% (95% confidence interval [CI] 77-90%) with PSMA PET/CT and 62% (95% CI 53-70%) with mpMRI (p < 0.001). Per-lesion sensitivity for csPCa was 95% (95% CI 88-98%) with PSMA PET/CT and 73% (95% CI 63-81%) with mpMRI (p < 0.001). The diagnostic accuracy of PSMA PET/CT and mpMRI for detection of EPE per lesion did not significantly differ (sensitivity 45%, 95% CI 31-60% vs 55%, 95% CI 40-69%; p = 0.3; specificity 85%, 95% CI 75-92% vs 90%, 95% CI 81-86%; p = 0.5). The sensitivity and specificity of PSMA PET/CT and mpMRI for detection of SVI did not significantly differ (sensitivity 47%, 95% CI 21-73% vs 33%, 95% CI 12-62; p = 0.6; specificity 94%, 95% CI 88-98% vs 96%, 95% CI 90-99%; p = 0.8). CONCLUSIONS: 18F-PSMA-1007 is a promising imaging modality for localising intraprostatic csPCa but did not show additional value in assessing EPE and SVI in comparison to mpMRI. PATIENT SUMMARY: A new imaging technique called PET/CT (positron emission tomography/computed tomography) with the radioactive tracer 18F-PSMA-1007 shows promise in identifying the location of clinically significant prostate cancer. However, it does not seem to be of additional value over magnetic resonance imaging (MRI) for determining the local tumour stage.
引用
- Exterkate L, Hermsen R, Küsters-Vandevelde HVN, et al. Head-to-Head Comparison of 18F-PSMA-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging with Whole-mount Histopathology as Reference in Localisation and Staging of Primary Prostate Cancer. Eur Urol Oncol. 2023. PMID: 37230883. doi:10.1016/j.euo.2023.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。